Sarcoidosis: Clinical manifestations, staging and therapy (part II)

Respiratory Medicine

Volumn 92, Issue 2, 1998, Pages 140-149

  Muller Quernheim J ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MARKER; METHOTREXATE; PENTOXIFYLLINE; THALIDOMIDE;

CLINICAL FEATURE; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LUNG FIBROSIS; LUNG LAVAGE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; STAGING;

EID: 0031929213     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90086-5     Document Type: Review

References (129)

1. Teirstein AS, Lesser M. Worldwide distribution and epidemiology of sarcoidosis. In: Fanburg B, ed. Sarcoidosis and Other Granulomatous Diseases of the Lung. Basel: Dekker, 1983: 101-134.
2. Thomas PD, Hunninghake GW. Current concepts of pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135: 747-760.
3. Mitchell DN, Scadding JN. Sarcoidosis. Am Rev Respir Dis 1974; 110: 774-802.
4. Konietzko N, Faupel-Bauer B, Kraft J. Die Atemwege bei Sarkoidose. Dtsch Med Wochenschr 1987; 112: 1772-1778.
5. Meier-Sydow J, Gebhardt T, Kronenberger H et al. Diffuse pulmonary fibrosis with airflow obstruction - Clinical entities and classification. Prax Klin Pneumol 1983; 37: 335-341.
6. Nowak D, Kanzow G, Magnussen H. Patienten mit Sarkoidose haben gehäuft eine bronchiale Hyperreaktivität. Pneumologie 1990; 44: 572-573.
7. Bechtel J, Starr III T, Dantzker D, Bower J. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis 1981; 124: 759-761.
8. Mitchell D, Scadding J, Heard B, Hinson K. Sarcoidosis: Histopathological definition and clinical diagnosis. J Clin Path 1977; 30: 395-408.
9. Crystal RG, Bitterman PB, Rennard SI, Keogh BA. Interstitial lung disease of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154-156, 235-244.
10. Crystal RG, Hunninghake GW, Gadek JE, Keogh BA, Rennard SI, Bitterman PB. The pathogenesis of sarcoidosis. Paris: Pergamon Press, 1983: 13-35. (Chretien J, Marsac J, Saltiel JC, ed., Proceedings of the International Conference on Sarcoidosis and Other Granulomatous Disorders).
11. Cole S, Johnson K, Ward P. Pathology of sarcoidosis, granulomatous vasculitis, and other idiopathic granulomatous diseases of the lung. In: Fanburg B, ed. Sarcoidosis and Other Granulomatous Diseases of the Lung. Basel: Dekker, 1983: 149-202.
12. Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and medistinal lymphadenopathy due to photocopier toner dust. Lancet 1996; 348: 690.
13. James DG. Mimics of sarcoidosis, oro-facial granulomatosis (Melkersson-Rosenthal Syndrome). Sarcoidosis 1991; 8: 84.
14. du Bois RM. Mimics of sarcoidosis, extrinsic allergic alveolitis. Sarcoidosis 1991; 8: 85-88.
15. Daly PD, O'Brian DS, Robinson I, Prichard JS. Hodgkin's disease with a granulomatous pulmonary presentation mimicking sarcoidosis. Thorax 1988; 43: 407-409.
16. Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer 1986; 54: 467-473.
17. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: Identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145: 1212-1214.
18. Müller-Quernheim J, Zissel G, Schopf R, Vollmer E, Schlaak M. Differentialdiagnose Berylliose/ Sarkoidose bei einem Zahntechniker. Dtsch Med Wochenschr 1996; 121: 1462-1466.
19. Kent DC, Houk VN, Elliott RC, Sokolowski JW, Baker JH, Sorensen K. The definitive evaluation of sarcoidosis. Am Rev Respir Dis 1970; 101: 721-727.
20. Hunninghake GW, Gilbert S, Pueringer R et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-898.
21. Sones M. Israel H. Course and prognosis of sarcoidosis. Am J Med 1960; 29: 64.
22. Stone D, Schwartz A. A long term study of sarcoid and its modification by steroid therapy. Lung function and other factors of prognosis. Am J Med 1966; 41: 528.
23. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994; 11: 123-125.
24. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993; 6: 349-353.
25. Martinetti M, Tinelli R, Kolek V et al. 'The sarcoidosis map': A joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152: 557-564.
26. Israel H, Karlin P, Menduke H, DeLisser O. Factors affecting outcome of sarcoidosis: Influence of race, extrathoracic involvement, and initial radiologic lung lesions. Ann NY Acad Sci 1986; 465: 609-618.
27. Olive K, Kataria Y. Cutaneous manifestations of sarcoidosis. Relationships to other organ system involvement, abnormal laboratory measurements, and disease course. Arch Intern Med 1985; 145: 1811-1814.
28. duBois R. Diffuse lung disease: an approach to management. Brit Med J 1994; 309: 175-179.
29. Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 1990; 142: 1206-1215, 1440-1448.
30. Verstraeten A, Demedts M, Verwilghen J et al. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 1990; 98: 560-567.
31. Greening AP, Nunn P, Dobson N, Rudolf M, Rees ADM. Pulmonary sarcoidosis: alterations in bronchoalveolar lymphocytes and T cell subsets. Thorax 1985; 40: 278-283.
32. Ward K, O'Connor C, Odium C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: The critical influence of disease presentation. Thorax 1989; 44: 6-12.
33. Merchant R, Schwartz D, Helmers R, Dayton C, Hunninghake G. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis 1992; 146: 448-453.
34. American Thoracic Society. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990; 142: 481-486.
35. Lavoilette M, La Forge J, Tennina S, Boulet L. Prognostic value of lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest 1991; 100: 380-384.
36. Ziegenhagen M, Benner UK, Zissel G, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNFα release of alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-1592.
37. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 713-719.
38. Müller-Quernheim J, Pfeifer S, Kienast K, Zissel G. Spontaneous interleukin-2 release of bronchoalveolar lavage cells in sarcoidosis is a co-determinator of prognosis. Lung 1996; 174: 243-253.
39. 2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993; 103: 832-838.
40. Lieberman J. Elevation of serum angiotensin-converting enzyme (ACE) level in sarcoidosis. Am J Med 1975; 59: 365-372.
41. Klockars M, Selroos O. Immunohistochemical demonstration of lysozyme in the lymph notes and Kveim reaction papules in sarcoidosis. Acta Pathol Microbiol Scand Sect A 1977; 85: 169-173.
42. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Respir Cell Mol Biol 1989; 1: 439-447.
43. Prior C, Barbee RA, Evans PM et al. Lavage versus serum measurement of lysozyme, angiotensin converting enzyme and other inflammatory markers in sarcoidosis. Eur Respir J 1990; 3: 1146-1154.
44. Specks U, Martin II WJ, Rohrbach MS. Bronchoalveolare lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990; 141: 117-123.
45. Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis 1993; 148: 483-486.
46. Muthuswamy PP, Lopez-Majano V, Ranginwala M, Trainor WD. Serum angiotensin-converting enzyme (SACE) activity as indicator of total body granuloma load and prognosis in sarcoidosis. Sarcoidosis 1987; 4: 142-148.
47. Fanburg BL. Serum angiotensin 1-converting enzyme in the diagnosis and determination of activity of sarcoidosis. In: Fanburg BL, ed. Sarcoidosis and other granulomatous diseases of the lung. Basel: Dekker, 1983: 263-272.
48. Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-316.
49. Eklund A, Blaschke E. Elevated serum neopterin in sarcoidosis. Lung 1986; 164: 325-332.
50. Prior C, Frank A, Fuchs D et al. Urinary neopterin excretion in pulmonary sarcoidosis: correlation to clinical course of disease. Clin Chim Acta 1988; 177: 211-220.
51. Homolka J, Lorenz J, Zuchhold HD, Müller-Quernheim J. Evaluation of soluble CD14 and serum neopterin as serum parameters of inflammatory activity of pulmonary sarcoidosis. Clin Investig 1992; 70: 909-916.
52. Homolka J, Müller-Quernheim J. Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis. Lung 1993; 171: 173-183.
53. Meliconi R, Lalli E, Borzi R et al. Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome. Thorax 1990; 45: 536-540.
54. Rubin LA, Kurman CC, Fritz ME et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells. J Immunol 1985; 135: 3172-3177.
55. Reske-Kunz AB, Osawa H, Josimovic-Alasevic O, Rüde E, Diamantstein T. Soluble interleukin-2 receptors are released by long term-cultured insulin-specific T cells transiently after contact with antigen. J Immunol 1987; 138: 192-196.
56. Semenzato G, Cipriani A, Trentin L et al. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis 1987; 4: 25-27.
57. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentration of soluble interleukin-2 receptors in serum samples and bronchoalveolar fluids in active sarcoidosis. Am Rev Respir Dis 1988; 137: 759-764.
58. Müller-Quernheim J, Pfeifer S, Strausz J, Ferlinz R. Correlation of clinical and immunological parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis 1991; 144: 1322-1329.
59. Ina Y, Takada K, Sato T, Yamamoto M, Noda M, Morishita M. Soluble interleukin 2 receptor in patients with sarcoidosis. Possible origin. Chest 1992; 102: 1128-1133.
60. Pforte A, Brunner A, Gais P et al. Concomitant modulation of serum-soluble interleukin-2 receptor and alveolar macrophage interleukin-2 receptor in sarcoidosis. Am Rev Respir Dis 1993; 147: 717-722.
61. Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992; 145: 187-192.
62. Planes C, Valeyre D, Loiseau A, Bernaudin J, Soler P. Ultrastructural alterations of the air-blood barrier in sarcoidosis and hypersensitivity pneumonitis and their relation to lung histopathology. Am J Respir Crit Care Med 1994; 150: 1067-1074.
63. Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentrations of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98: 1125-1129.
64. Strausz J, Müller-Quernheim J, Ferlinz R. Serumspiegel des sezernierten Interleukin-2 Rezeptor als ein Aktivitätsparameter der Sarkoidose. Dtsch Med Wochenschr 1989; 114: 744-749.
65. Agostini C, Zambello R, Sancetta R et al. Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease. Am J Respir Crit Care Med 1996; 153: 1359-1367.
66. Hol BEA, Hintzen RQ, van Lier RAW, Alberts C, Out TA, Jansen HM. Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis. Am Rev Respir Dis 1993; 148: 643-649.
67. Ito M, Kojiro N, Shirasaka T, Moriwaki Y, Tachibana I, Kokubu T. Elevated levels of soluble interleukin-2 receptors in tuberculous pleural effusions. Chest 1990; 97 (5): 1141-1143.
68. Baganha MF, Pego A, Lima MA, Gaspar EV, Cordeiro AR. Serum and pleural adenosine deaminase. Correlation with lymphocytic populations. Chest 1990; 97 (3): 605-610.
69. Fukami R, Ohba S, Ishida K, Nakamura S, Konno M, Ohno S. Serum adenosine deaminase and angiotensin converting enzyme activity in patients with endogenous uveitis. Acta Soc Ophthalmol Japan 1994; 98 (3): 287-292.
70. Taylor A. Serum adenosine deaminase activity is increased in sarcoidosis. Clin Chem 1984; 30: 499-500.
71. Lorenz J, Wetzel E, Müller-Quernheim J, Ferlinz R. Adenosin deaminase: A novel serum marker of disease activity in sarcoidosis. Am Rev Respir Dis 1994; 149: A609.
72. Peters U, Papadopoulos T, Müller-Hermelink H. MHC class II antigens on lung epithelia of human fetuses and neonates. Ontogeny and expression in lungs with histologie evidence of infection. Lab Invest 1990; 63: 38-13.
73. Cunningham AC, Milne DS, Wilkes J, Dark JH, Tetley TD, Kirby JA. Constitutive expression of MHC and adhesion molecules by alveolar epithelial cells (type II pneumocytes) isolated from human lung and comparison with immunocytochemical findings. J Cell Sci 1994; 107 (Pt 2): 443-449.
74. Guzman J, Izumi T, Nagai S, Costabel U. ICAM-1 and intergrin expression on isolated human alveolar type II pneumocytes. Eur Respir J 1994; 7: 736-739.
75. Shakoor Z, Hamblin AS. Increased CD11/CD18 expression on peripheral blood leucocytes of patients with sarcoidosis. Clin Exp Immunol 1992; 90: 99-105.
76. Striz I, Wang Y, Kalaycioglu O, Costabel U. Expression of alveolar macrophage adhesion molecules in pulmonary sarcoidosis. Chest 1992; 102: 882-886.
77. van Dinther-Janssen AC, van Maarssseveen TC, Eckert H, Newman W, Meijer CJ. Identical expression of ELAM-1, VCAM-1, and ICAM-1 in sarcoidosis and usual interstitial pneumonitis. J Pathol 1993; 170: 157-164.
78. Rothlein R, Mainolfi E, Czajkowski M, Marlin S. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-3793.
79. Ishii Y, Kitamura S. Elevated levels of soluble ICAM-1 in serum and BAL fluid in patients with active sarcoidosis. Chest 1995; 107: 1636-1640.
80. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J. Shed sICAM-1 molecules in BAL cell supernatants and serum of patients with pulmonary sarcoidosis. Lung 1997; 105-116.
81. Shijubo N, Imai K, Shigehara K et al. Soluble intercellular adhesion molecule-1 (ICAM-1) in sera and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Clin Exp Immunol 1994; 95: 156-161.
82. Hamblin AS, Shakoor Z, Kapahi P, Haskard D. Circulating adhesion molecules in sarcoidosis. Clin Exp Immunol 1994; 96: 335-338.
83. Kallenberg C, Shilizzi B, Beaumont F, de Leij L, Poppema S, The T. Expression of class II major histocompatibility complex antigens on alveolar epithelium in interstitial lung disease: relevance to pathogenesis of idiopathic pulmonary fibrosis. J Clin Pathol 1987; 40: 725-733.
84. Limper A, Colby V, Sanders M, Asakura S, Roche P, DeRemee R. Immunohistochemical localization of transforming growth factor-β1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med 1994; 149: 197-204.
85. Christensen P, Armstrong L, Fak J, Chen G, McDonald R, Toews G. Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cell-derived granulocyte macrophage-colony stimulating factor. Am J Respir Cell Mol Biol 1995; 13.
86. Paine RI, Mody CH, Chawis A, Spahr MA, Turka LA, Toews GB. Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol 1991; 5: 221-229.
87. Borron P, Veldhuizen RA, Lewis JF et al. Surfactant associated protein-A inhibits human lymphocyte proliferation and IL-2 production. Am J Respir Cell Mol Biol 1996; 15 (1): 115-121.
88. Standiford T, Kunkel S, Basha M et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networking in the lung. J Clin Invest 1990; 86: 1945-1953.
89. Standiford T, Kunkel S, Phan S, Rollins B, Strieter R. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem 1991; 266: 9912-9918.
90. Kohno N, Awaya Y, Oyama T et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 637-642.
91. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996; 109: 1277-1282.
92. Pohl WR, Conlan MG, Thompson AB et al. Vitronectin in bronchoalveolar lavage fluid is increase in patients with interstitial lung disease. Am Rev Respir Dis 1991; 143: 1369-1375.
93. Pohl WR, Thompson AB, Köhn H et al. Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study. Am Rev Respir Dis 1992; 145: 412-417.
94. Agostini C, Garbisa S, Trentin L et al. Pulmonary alveolar macrophages from patients with active sarcoidosis express type IV collagenolytic proteinase. Enzymatic mechanism for influx of mononuclear phagocytes at sites of disease activity. J Clin Invest 1989; 84: 605-612.
95. Eklund A, Sigurdardottir O, Öhrn M. Vitronectin and its relationship to other extracellular matrix components in bronchoalveolar matrix components in bronchoalveolar lavage fluid in sarcoidosis. Am Rev Respir Dis 1992; 145: 646-650.
96. Fanburg B. Treatment of sarcoidosis. In: Fanburg B, ed. Sarcoidosis and Other Granulomatous Diseases of the Lung. Basel: Dekker, 1983: 381-388. (Lenfant C, ed., Lung Biology in Health and Disease; Vol. 20).
97. DeRemee R. The present status of treatment of pulmonary sarcoidosis: A house divided. Chest 1977; 71: 388-393.
98. Sharma O. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147: 1598-1600.
99. DuBois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J 1994; 7: 1203-1209.
100. Wurm K, Reindell H, Heilmayer L. Der Lungenboeck im Röntgenbild. Stuttgart: Georg Thieme, 1958.
101. Alberts C, van der Mark T, Jansen H. Dutch Study Group on Pulmonary Sarcoidosis. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995; 8: 682-688.
102. Milman N, Graudal N, Grode G, Munch E. No effects of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Internal Med 1994; 236: 285-290.
103. Kirsten D. Inhaled steroids for sarcoidosis. Eur Respir J 1995; 8: 679-680.
104. Martinet Y, Pinkston P, Saltini C, Spurzem J, Müller-Quernheim J, Crystal RG. Evaluation of the in vitro and in vivo effects of cyclosporine on the T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis 1988; 138: 1242-1248.
105. Rebuck A, Stiller C, Braude A, Laupache A, Cohen R, Chapman K. Cyclosporin for pulmonary sarcoidosis. Lancet 1984; i: 1174.
106. Rebuck A, Sander B, MacFadden D, Man S, Cohen R. Cyclosporin in pulmonary sarcoidosis. Lancet 1987; i: 1486.
107. York E, Kovithavongs T, Man P, Rebuck A, Sproule B. Cyclosporin and chronic sarcoidosis. Chest 1990; 98: 1026-1029.
108. Hammond J, Bateman E. Successful treatment of life-threatening steroid-resistant pulmonary sarcoidosis with cyclosporin in a patient with systemic lupus erythematodous. Respir Med 1990; 84: 77-80.
109. Cunnah D, Chew S, Wass J. Cyclosporin for central nervous system sarcoidosis. Am J Med 1988; 85: 580-581.
110. Kavanaugh A, Andrew S, Cooper B, Lawrence E, Huston D. Cyclosporin therapy of central nervous system sarcoidosis. Am J Med 1987; 82: 387.
111. Kataria Y. Chlorambucil in sarcoidosis. Chest 1980: 78: 36-43.
112. Cagnoni M, Lombardi A, Matucci Cerinic M, Dedola G, Pignone A. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 346: 1229-1230.
113. Hof DG, Hof PC, Godfrey WA. Long-term use of azathioprine as a steroid-sparing treatment for chronic sarcoidosis. Am J Respir Crit Care Med 1996; 153: A870.
114. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996; 15: 59-64.
115. Liedtka JE. Intralesional chloroquine for the treatment of cutaneous sarcoidosis (letter). Int J Dermatol 1996; 35 (9): 682-683.
116. Zic JA, Horowitz DH, Arzubiaga C, King LE Jr. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127 (7): 1034-1040.
117. Brownstein S, Liszauer AD, Carey WD, Nicolle DA. Sarcoidosis of the eyelid skin. Can J Ophthalmol 1990; 25 (5): 256-259.
118. Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metabol 1987; 65 (6): 1201-1209.
119. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Int Med 1989; 111 (5): 437-438.
120. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986; 315: 727-730.
121. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990; 142: 1268-1271.
122. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/ tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 1990; 172 (1): 391-394.
123. Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merrill JE. Immunoregulatory molecules and IL2 receptors identified in multiple sclerosis brain. J Immunol 1986; 136: 3239-3245.
124. Zabel P, Schade U, Schlaak M. Inhibition of endogenous TNF-formation by Pentoxifylline. Immunobiol 1993; 187: 447-463.
125. Funk J, Ernst M, Schlaak M, Zabel P. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporine. Int J Immunopharmacol 1995; 17: 1007-1016.
126. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173 (3): 699-703.
127. Zabel P, Entzian P, Da lhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669.
128. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32 (5 Pt 2): 866-869.
129. Pforte A, Schiessler A, Gais P et al. Expression of CD14 correlates with lung function impairment in pulmonary sarcoidosis. Chest 1994; 105: 349-354.